Monday, 15 Mar 2021 07:07 AM MYT
Doses of the Oxford University/AstraZeneca Covid-19 vaccine are logged by a technical officer, after they arrive at the Princess Royal Hospital in Haywards Heath, West Sussex, Britain, January 2, 2021. Pool picture via Reuters
Subscribe to our Telegram channel for the latest updates on news you need to know.
MARCH 15 AstraZeneca Plc said yesterday a review of safety data of people vaccinated with its Covid-19 vaccine has shown no evidence of an increased risk of blood clots.
AstraZeneca’s review, which covered more than 17 million people vaccinated in the United Kingdom and European Union, comes after health authorities in some countries suspended the use of its vaccine over clotting issues.
ZURICH, March 7 Austrian authorities have suspended inoculations with a batch of AstraZeneca’s Covid-19 vaccine as a precaution while investigating the death of one person and the illness of another after the shots, a health agency said today. “The Federal Office for Safety in Health Care.
At present, India is giving the second dose of Covishield after a gap of 28 days. However, new evidence suggests that efficacy is better when the second dose is given after 8-12 weeks.